Eli Lilly and Co (LLY)
770.00
-1.12
(-0.15%)
USD |
NYSE |
May 17, 16:00
770.99
+0.99
(+0.13%)
After-Hours: 20:00
Eli Lilly SG&A Expense (TTM): 6.912B for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 6.912B |
December 31, 2023 | 6.710B |
September 30, 2023 | 6.517B |
June 30, 2023 | 6.328B |
March 31, 2023 | 6.049B |
December 31, 2022 | 5.880B |
September 30, 2022 | 6.129B |
June 30, 2022 | 6.020B |
March 31, 2022 | 6.104B |
December 31, 2021 | 6.142B |
September 30, 2021 | 6.119B |
June 30, 2021 | 6.069B |
March 31, 2021 | 5.867B |
December 31, 2020 | 5.869B |
September 30, 2020 | 6.019B |
June 30, 2020 | 5.924B |
March 31, 2020 | 6.048B |
December 31, 2019 | 6.004B |
September 30, 2019 | 5.984B |
June 30, 2019 | 6.019B |
March 31, 2019 | 5.913B |
December 31, 2018 | 5.735B |
September 30, 2018 | 5.603B |
June 30, 2018 | 5.723B |
March 31, 2018 | 5.958B |
Date | Value |
---|---|
December 31, 2017 | 6.180B |
September 30, 2017 | 6.354B |
June 30, 2017 | 6.404B |
March 31, 2017 | 6.361B |
December 31, 2016 | 6.330B |
September 30, 2016 | 6.460B |
June 30, 2016 | 6.471B |
March 31, 2016 | 6.483B |
December 31, 2015 | 6.533B |
September 30, 2015 | 6.534B |
June 30, 2015 | 6.631B |
March 31, 2015 | 6.659B |
December 31, 2014 | 6.621B |
September 30, 2014 | 6.774B |
June 30, 2014 | 6.755B |
March 31, 2014 | 6.958B |
December 31, 2013 | 7.126B |
September 30, 2013 | 7.150B |
June 30, 2013 | 7.254B |
March 31, 2013 | 7.318B |
December 31, 2012 | 7.514B |
September 30, 2012 | 7.669B |
June 30, 2012 | 7.830B |
March 31, 2012 | 7.942B |
December 31, 2011 | 7.880B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
5.867B
Minimum
Mar 2021
6.912B
Maximum
Mar 2024
6.136B
Average
6.048B
Median
SG&A Expense (TTM) Benchmarks
Amgen Inc | 6.729B |
Biogen Inc | 2.526B |
Johnson & Johnson | 21.93B |
Vertex Pharmaceuticals Inc | 1.238B |
Viking Therapeutics Inc | 37.46M |